KRAS and cancer: Patients with KRAS G12R vs. non-G12R mutated cancers had significantly longer median OS (20.4 vs. 14.3 months, P = .0047) and PFS (12.2 vs. 6.8 months, P = .009) (Fig 2A, 2B).